Nestlé to Acquire Aimmune Therapeutics for $2.6B

 Nestlé to Acquire Aimmune Therapeutics for $2.6B

Nestlé to Acquire Aimmune Therapeutics for $2.6B

Shots:

  • Nestle to acquire all outstanding shares of Aimmune’s common stock for $34.50/share in cash, making a total deal value as $2.6B, representing a 174% premium to Aimmune’s closing share price on Aug 28, 2020, of $12.60. The transaction is expected to close in Q4’20
  • The acquisition extends Nestle’s food allergy portfolio with the addition of Palforzia, creating a broader spectrum of solutions for children living with food allergies
  • Aimmune’s Palforzia is the first and only FDA-approved treatment, which helps in reducing the frequency and severity of the allergic reaction to peanuts, including anaphylaxis, in children aged 4-17yrs.

Click here ­to­ read full press release/ article | Ref: Aimmune | Image: European Coatings

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post